{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:25:13Z","timestamp":1793053513428,"version":"4.5.0"},"reference-count":41,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>(1) Background: In patients with heart failure (HF) and impaired nutritional status or decreased muscle mass, sodium-glucose cotransporter-2 inhibitors (SGLT2is) may worsen these conditions and result in poor prognosis, especially worsening of frailty. We aimed to investigate the relationship between SGLT2is and clinical outcomes, including frailty-related events, in patients with HF and malnutrition, frailty, sarcopenia, or cachexia. (2) Methods: In this retrospective observational cohort study, a global federated health research network provided data on patients with HF and malnutrition, frailty, sarcopenia, or cachexia from January 2016 to December 2021. We investigated the incidence of the composite endpoint of death or frailty-related events within one year. (3) Results: Among 214,778 patients included in the analysis, 4715 were treated with SGLT2is. After propensity score matching, 4697 patients in the SGLT2is group were matched with 4697 patients in the non-SGLT2is groups. The incidence of the composite endpoint, mortality, and frailty-related events was lower in the SGLT2is group than in the non-SGLT2is group (composite endpoint, 65.6% versus 77.6%, p &lt; 0.001; mortality, 17.4% vs. 35.5%, p &lt; 0.001; frailty-related events, 59.4% vs. 64.3%, p &lt; 0.001). (4) Conclusions: Patients with HF and malnutrition, frailty, sarcopenia, or cachexia had a high incidence of death and frailty-related events. SGLT2is were associated with a lower incidence of these events.<\/jats:p>","DOI":"10.3390\/jcm13061670","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T04:47:05Z","timestamp":1710478025000},"page":"1670","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure with Malnutrition, Frailty, Sarcopenia, or Cachexia"],"prefix":"10.3390","volume":"13","author":[{"given":"Yu","family":"Horiuchi","sequence":"first","affiliation":[{"name":"Division of Cardiology, Mitsui Memorial Hospital, Tokyo 101-8643, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2102-033X","authenticated-orcid":false,"given":"Masahiko","family":"Asami","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Mitsui Memorial Hospital, Tokyo 101-8643, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Yahagi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Mitsui Memorial Hospital, Tokyo 101-8643, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asahi","family":"Oshima","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Mitsui Memorial Hospital, Tokyo 101-8643, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Gonda","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Mitsui Memorial Hospital, Tokyo 101-8643, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1554-9428","authenticated-orcid":false,"given":"Daiki","family":"Yoshiura","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Mitsui Memorial Hospital, Tokyo 101-8643, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0612-4130","authenticated-orcid":false,"given":"Kota","family":"Komiyama","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Mitsui Memorial Hospital, Tokyo 101-8643, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Yuzawa","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Mitsui Memorial Hospital, Tokyo 101-8643, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Mitsui Memorial Hospital, Tokyo 101-8643, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiro","family":"Aoki","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Mitsui Memorial Hospital, Tokyo 101-8643, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Tanabe","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Mitsui Memorial Hospital, Tokyo 101-8643, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/ejhf.1611","article-title":"Heart Failure Association\/European Society of Cardiology position paper on frailty in patients with heart failure","volume":"21","author":"Vitale","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s12272-021-01349-z","article-title":"Understanding of sarcopenia: From definition to therapeutic strategies","volume":"44","author":"Kim","year":"2021","journal-title":"Arch. Pharm. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/ejhf.1926","article-title":"Prevalence and prognostic impact of the coexistence of multiple frailty domains in elderly patients with heart failure: The FRAGILE-HF cohort study","volume":"22","author":"Matsue","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/heartjnl-2016-309995","article-title":"The challenge of frailty and sarcopenia in heart failure with preserved ejection fraction","volume":"103","author":"Kinugasa","year":"2017","journal-title":"Heart"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.amjms.2022.08.016","article-title":"The complex pathophysiology of cardiac cachexia: A review of current pathophysiology and implications for clinical practice","volume":"365","author":"Thanapholsart","year":"2023","journal-title":"Am. J. Med. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.jacep.2017.06.012","article-title":"Utility of Frailty Assessment for Elderly Patients Undergoing Cardiac Resynchronization Therapy","volume":"3","author":"Kubala","year":"2017","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Keller, D.M., Ahmed, N., Tariq, H., Walgamage, M., Walgamage, T., Mohammed, A., Chou, J.T., Kaluzna-Oleksy, M., Lesiak, M., and Straburzynska-Migaj, E. (2022). SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure-A Concise Review. J. Clin. Med., 11.","DOI":"10.3390\/jcm11061470"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.jacc.2018.06.040","article-title":"Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review","volume":"72","author":"Zelniker","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3390\/diabetology4030022","article-title":"Sodium-Glucose Co-Transporter 2 Inhibitors as a Powerful Cardioprotective and Renoprotective Tool: Overview of Clinical Trials and Mechanisms","volume":"4","year":"2023","journal-title":"Diabetology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/S2665-9913(20)30422-7","article-title":"Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: A cohort study","volume":"3","author":"Jorge","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.cardfail.2022.05.001","article-title":"Prognostic Interplay between COVID-19 and Heart Failure with Reduced Ejection Fraction","volume":"28","author":"Greene","year":"2022","journal-title":"J. Card. Fail."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e021970","DOI":"10.1161\/JAHA.121.021970","article-title":"Atrial Fibrillation in Patients with Cardiomyopathy: Prevalence and Clinical Outcomes From Real-World Data","volume":"10","author":"Buckley","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e026759","DOI":"10.1136\/bmjopen-2018-026759","article-title":"Dr Foster global frailty score: An international retrospective observational study developing and validating a risk prediction model for hospitalised older persons from administrative data sets","volume":"9","author":"Soong","year":"2019","journal-title":"BMJ Open"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/S0140-6736(18)30668-8","article-title":"Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: An observational study","volume":"391","author":"Gilbert","year":"2018","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1001\/jama.290.19.2581","article-title":"Predicting mortality among patients hospitalized for heart failure: Derivation and validation of a clinical model","volume":"290","author":"Lee","year":"2003","journal-title":"JAMA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.cardfail.2004.02.011","article-title":"Risk stratification after hospitalization for decompensated heart failure","volume":"10","author":"Felker","year":"2004","journal-title":"J. Card. Fail."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jacc.2009.08.083","article-title":"Triage after hospitalization with advanced heart failure: The ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score","volume":"55","author":"Hasselblad","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa0706824","article-title":"Cardiac troponin and outcome in acute heart failure","volume":"358","author":"Peacock","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/ejhf.2707","article-title":"Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: A secondary analysis of EMPEROR-Reduced","volume":"24","author":"Filippatos","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1161\/CIRCULATIONAHA.119.044133","article-title":"Efficacy and Safety of Dapagliflozin in Heart Failure with Reduced Ejection Fraction According to Age: Insights From DAPA-HF","volume":"141","author":"Martinez","year":"2020","journal-title":"Circulation"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e010080","DOI":"10.1161\/CIRCHEARTFAILURE.122.010080","article-title":"Efficacy and Safety of Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial","volume":"15","author":"Peikert","year":"2022","journal-title":"Circ. Heart Fail."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1161\/CIRCULATIONAHA.122.061754","article-title":"Efficacy and Safety of Dapagliflozin According to Frailty in Patients with Heart Failure: A Prespecified Analysis of the DELIVER Trial","volume":"146","author":"Butt","year":"2022","journal-title":"Circulation"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"820","DOI":"10.7326\/M21-4776","article-title":"Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure with Reduced Ejection Fraction: A Post Hoc Analysis of the DAPA-HF Trial","volume":"175","author":"Butt","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: The pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jdi.12851","article-title":"Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: The Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study","volume":"10","author":"Sasaki","year":"2019","journal-title":"J. Diabetes Investig."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1042\/BCJ20210700","article-title":"Differential effect of canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on slow and fast skeletal muscles from nondiabetic mice","volume":"479","author":"Otsuka","year":"2022","journal-title":"Biochem. J."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kashima, A., Kamiya, K., Hamazaki, N., Ueno, K., Nozaki, K., Ichikawa, T., Yamashita, M., Uchida, S., Noda, T., and Hotta, K. (2022). Association between SGLT2 Inhibitors and Cardiac Rehabilitation Outcomes in Patients with Cardiovascular Disease and Type 2 Diabetes Mellitus. J. Clin. Med., 11.","DOI":"10.3390\/jcm11195956"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized Trial of Empagliflozin in Nondiabetic Patients with Heart Failure and Reduced Ejection Fraction","volume":"77","author":"Mancini","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/ejhf.2560","article-title":"Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO(2)): A randomized clinical trial","volume":"24","author":"Palau","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","article-title":"Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial","volume":"141","author":"Kosiborod","year":"2020","journal-title":"Circulation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.121.057812","article-title":"Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial","volume":"145","author":"Butler","year":"2022","journal-title":"Circulation"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/eurheartj\/ehaa1007","article-title":"Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: The EMPEROR-Reduced trial","volume":"42","author":"Butler","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"790251","DOI":"10.3389\/fnagi.2021.790251","article-title":"Relationships among Cognitive Function, Frailty, and Health Outcome in Community-Dwelling Older Adults","volume":"13","author":"Xue","year":"2021","journal-title":"Front. Aging Neurosci."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/6\/1670\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:13:33Z","timestamp":1760105613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/6\/1670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,14]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["jcm13061670"],"URL":"https:\/\/doi.org\/10.3390\/jcm13061670","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,14]]}}}